A trial to see if other drugs affect the way bortezomib works in people with non Hodgkin lymphoma and myeloma

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Blood cancers
Non-Hodgkin lymphoma




Phase 1

This trial is looking at whether other drugs affect the way the body breaks down bortezomib (Velcade) in people with non Hodgkin lymphoma or myeloma that has continued to grow.

More about this trial

Bortezomib is a type of biological therapy called a proteasome inhibitor. Doctors use it to treat myeloma that has come back after treatment. Clinical trials are currently looking at using bortezomib for people with non Hodgkin lymphoma.

This trial is looking at the effect of two drugs on bortezomib. The first is rifampicin. Rifampicin is not used to treat cancer. It is an antibiotic used to treat or prevent infections. The second is a steroid called dexamethasone. These two drugs activate an enzyme Open a glossary item in the body called CYP3A4.

The CYP3A4 enzyme breaks down bortezomib. Doctors think that rifampicin and dexamethasone will lower the amount of bortezomib because they increase the amount of the CYP3A4 enzyme. This may affect the way that bortezomib works. But researchers are not sure yet.

The results of this study may help doctors to improve treatment for people with myeloma and non Hodgkin lymphoma in the future.

Summary of results

Despite attempting to contact the trial team, we have been unable to check the results of this trial.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Simon Rule

Supported by

Johnson and Johnson Pharmaceutical R+D

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think